Quest Diagnostics (DGX) Earnings Date & Reports
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US... Show more
DGX is expected to report earnings to rise 12.80% to $2.82 per share on July 23
Quest Diagnostics (DGX) Q1 2026 Earnings Recap: Beats on Revenue and EPS, Raises Outlook
Key Takeaways
- Quest Diagnostics reported Q1 2026 revenue of $2.895 billion, up 9.2% year-over-year (YoY), surpassing consensus estimates of approximately $2.83 billion.+Tops+Q1+EPS+by+13c,+Beats+on+Revenue;+Offers+FY26+Guidance/26339589.html)
- Adjusted diluted earnings per share (EPS) reached $2.50, up 13.1% YoY and beating expectations around $2.37.
- Requisition volumes grew 10.9% YoY, driven by strong organic demand across channels.
- Company raised full-year 2026 guidance, now expecting revenue of $11.78 billion to $11.90 billion and adjusted EPS of $10.63 to $10.83.
- Shares rose in response to the results and upbeat guidance.
Earnings Context and Why It Matters
As the leading provider of diagnostic information services in the U.S., Quest Diagnostics' quarterly results offer critical insights into healthcare testing demand, reimbursement trends, and operational efficiency. Following a strong 2025 with double-digit revenue growth, investors watched Q1 2026 closely for signs of sustained volume recovery in physician, hospital, and consumer channels amid stabilizing post-pandemic testing volumes. This report matters as it signals the company's ability to navigate margin pressures from labor costs and payer mix shifts while capitalizing on advanced diagnostics growth. Strong results reinforce Quest's strategic focus on innovation and productivity, influencing sector peers and healthcare ETF positioning.
For the first quarter ended March 31, 2026, Quest Diagnostics delivered robust performance. Net revenues totaled $2.895 billion, a 9.2% increase from $2.652 billion in Q1 2025, with organic revenue growth of 9.0%. Diagnostic Information Services revenues, the core segment, rose 9.4% to $2.832 billion, fueled by 10.9% requisition volume growth (10.8% organic), though revenue per requisition dipped 1.3%.
Reported diluted EPS came in at $2.24, up 15.5% YoY, while adjusted diluted EPS of $2.50 rose 13.1% from $2.21, exceeding Wall Street consensus. Adjusted operating income increased 10.0% to $447 million, with margins steady at 15.4%. Cash from operations was $278 million.
The company also updated full-year 2026 guidance upward, projecting net revenues of $11.78 billion to $11.90 billion (6.8%-7.8% growth) and adjusted diluted EPS of $10.63 to $10.83, from prior ranges of $11.70 billion-$11.82 billion and $10.50-$10.70, respectively.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.
Market Reaction and Investor Sentiment
Quest Diagnostics shares advanced following the Q1 earnings release on April 21, 2026, reflecting positive investor response to the revenue and EPS beats, strong volume metrics, and raised full-year guidance. Pre-market and early trading gains highlighted approval of the company's organic growth momentum and margin resilience, alleviating concerns over reimbursement headwinds. Sentiment turned optimistic, with focus shifting to execution on the updated outlook amid favorable healthcare demand signals.
Forward Outlook and Key Factors to Monitor
Investors should track Quest Diagnostics' progress against its elevated 2026 guidance, particularly organic revenue growth in the 6.8%-7.8% range. Sustained requisition volume expansion across physician, hospital, and direct-to-consumer channels will be pivotal, building on Q1's double-digit gains.
Margin trends warrant attention, as productivity gains and cost controls supported adjusted operating margins near 15% in Q1. Ongoing investments in advanced diagnostics, like AI-enhanced tools, could drive higher revenue per requisition over time, offsetting payer mix pressures.
Upcoming catalysts include quarterly execution, reimbursement updates from Medicare and commercial payers, and integration of recent partnerships such as with Corewell Health. Broader industry dynamics, including flu season impacts and chronic testing demand, will influence results. Cash flow generation around $1.75 billion supports share repurchases and dividends, with capex steady at $550 million.
Monitor SEC filings and earnings calls for updates on these areas to gauge trajectory toward year-end targets.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Advertisement
General Information
a provider of diagnostic testing and information services
Industry MedicalSpecialties